6-K ·Filed Aug 13, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 3/10
Horizonweeks Processed1mo ago SEC0001575872-26-000568
Notable filing: 6-K
Actionable Insight • Neutral

Monitor for any subsequent announcements regarding a replacement for the CEO of API and Services, as the role is critical to the company's active pharmaceutical ingredients and services segment. The long notice period suggests an orderly transition, reducing near-term disruption risk.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+5d
RDY ▼ -2.50% at T+5d
NEUTRAL call ✗ call lost -2.50% · α vs SPY -0.53% · entry $12.42 → $12.11
Next anchor: T+20d due 21d ago
Latest observation: T+28 +14.02% FF3 residual α
Entry anchored
Aug 13, 09:52 AM ET
via 1-min bar
T+1d
-1.21%
call -1.21% · α -1.01%
$12.27
settled 7w ago
T+5d
-2.50%
call -2.50% · α -0.53%
$12.11
settled 6w ago
T+20d
—
call — · α —
—
due 21d ago
T+60d
—
call — · α —
—
in 5w

Price Chart

Loading chart...

Executive Summary

Dr. Reddy's Laboratories filed a 6-K disclosing the resignation of Mr. Deepak Sapra, CEO of API and Services and Senior Management Personnel, effective November 12, 2026, to pursue opportunities outside the company. This is a routine senior management departure with a standard notice period, and no financial impact or strategic shift is indicated.

Key Facts

  • Mr. Deepak Sapra resigned as CEO, API and Services and Senior Management Personnel.
  • Resignation effective from close of business on November 12, 2026.
  • He will remain with the company until the effective date to ensure a smooth transition.
  • He served at Dr. Reddy's for over 23 years since 2003.
  • Reason cited: to pursue opportunities outside the company.

Financial Impact

No financial impact disclosed; routine management change.

Risk Factors

  • Potential operational disruption if a suitable replacement is not identified before the effective date.
  • Loss of institutional knowledge from a 23-year veteran in a key business segment.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
31% bullish (45 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001575872-26-000568
Document: 0001575872-26-000568-index.html0001575872-26-000568
Document: 0001575872-26-000568.txt0001575872-26-000568
51 reports for RDY
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +23.28%Jun 26, 2026
Filters
Rows
Reports for RDY — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
6-K
NEUTRAL ★ 3/10
$11.91 $11.55▼ −3.02%▼ −2.56%$12.25 (+2.85%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 5/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Sep 10, 2026
22d ago
6-K
NEUTRAL ★ 2/10
$11.71 $11.90▲ +1.62%▲ +0.77%$12.25 (+4.61%)
Aug 26, 2026
5w ago
6-K
NEUTRAL ★ 2/10
$12.22 $12.16▼ −0.49%▼ −1.15%$12.25 (+0.25%)
Aug 17, 2026
6w ago
6-K
MIXED ★ 5/10
$12.11 $12.15▲ +0.33%▲ +1.01%$12.25 (+1.16%)
Aug 13, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$12.42 $12.27▼ −1.21%▼ −1.01%$12.25 (−1.37%)
Aug 10, 2026
7w ago
6-K
NEUTRAL ★ 2/10
$12.15 $12.45▲ +2.47%▲ +2.79%$12.25 (+0.82%)
Aug 3, 2026
8w ago
6-K
BULLISH ★ 6/10
$12.07 $12.10▲ +0.25%▼ −1.55%$12.25 (+1.49%)
Jul 29, 2026
9w ago
6-K
NEUTRAL ★ 4/10
$11.76 $11.83▲ +0.60%▼ −1.08%$12.25 (+4.17%)
Jul 23, 2026
10w ago
6-K
NEUTRAL ★ 2/10
$11.80 $11.79▼ −0.08%▼ −0.19%$12.25 (+3.81%)
Showing 10 of 51

US Market Status

Market Closed — Opens Mon (65h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access